Amicus Therapeutics

European Medicines Agency Validates Amicus Therapeutics Marketing Authorization Applications for AT-GAA for the Treatment of Pompe Disease

PHILADELPHIA, PA — Amicus Therapeutics (Nasdaq: FOLD) announced that the European Medicines Agency (EMA) recently validated the Marketing Authorization Applications (MAA) for AT-GAA, the Company’s investigational two-component therapy for the …

European Medicines Agency Validates Amicus Therapeutics Marketing Authorization Applications for AT-GAA for the Treatment of Pompe Disease Read More